Indian Immunologicals to expand operations in New Zealand
Indian Immunologicals's subsidiary inaugurated a new facility for the production of sterile-filtered serum
Pristine Biologicals NZ, a subsidiary of Indian Immunological, inaugurated a new facility for the production of sterile-filtered serum in New Zealand on 11th July, 2022, a statement from Indian Immunologicals said.
Meenesh C Shah, Chairman, Indian Immunologicals and National Dairy Development Board, in the presence of Dr Jason Smith, the Mayor of Dargaville; Dr K Anand Kumar, Managing Director, Indian Immunologicals; Dr Vijay Dasari, GM, and Director, Pristine Biologicals (NZ), and many dignitaries, inaugurated the facility, the statement added.
Many vaccine manufacturers in India have expressed difficulty in obtaining quality serum and have sought the help of IIL through government. The facility will ramp up serum production capacity at Pristine NZ and also make it available to Indian companies on a priority basis, according to the statement.